Long-Term Safety and Disease Control of Ruxolitinib Cream in Children Aged 2 to 6 and 7 to 11 Years: Results From the TRuE-AD3 Study

被引：0

作者：

Soong, Weily ^{[1
]}

Zaenglein, Andrea ^{[2
]}

Tollefson, Megha ^{[3
]}

Simpson, Eric ^{[4
]}

Devani, Alim ^{[5
]}

Joyce, Joel ^{[6
]}

Schlessinger, Joel ^{[7
]}

Siri, Dareen ^{[8
]}

Angel, Brett ^{[9
]}

Sturm, Daniel ^{[9
]}

Li, Qian ^{[9
]}

Paller, Amy ^{[10
]}

机构：

[1] AllerVie Hlth, Birmingham, AL USA

[2] Penn State Hershey Med Ctr, Hershey, PA USA

[3] Mayo Clin, Rochester, MN USA

[4] Oregon Hlth & Sci Univ, Portland, OR USA

[5] Dermatol Res Inst, Calgary, AB, Canada

[6] Endeavor Hlth, Skokie, IL USA

[7] Schlessinger MD, Omaha, NE USA

[8] Midwest Allergy SWIA Clin Res, Normal, IL USA

[9] Incyte Corp, Wilmington, DE USA

[10] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA

来源：

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

594

引用

页码：AB191 / AB191

页数：1